HIF-1 as a target for drug development - PubMed (original) (raw)
Review
doi: 10.1038/nrd1199.
Affiliations
- PMID: 14526383
- DOI: 10.1038/nrd1199
Review
HIF-1 as a target for drug development
Amato Giaccia et al. Nat Rev Drug Discov. 2003 Oct.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Similar articles
- HIFs, hypoxia, and vascular development.
Covello KL, Simon MC. Covello KL, et al. Curr Top Dev Biol. 2004;62:37-54. doi: 10.1016/S0070-2153(04)62002-3. Curr Top Dev Biol. 2004. PMID: 15522738 Review. - Hypoxia-inducible factor 1 (HIF-1) in cancer.
Quintero M, Mackenzie N, Brennan PA. Quintero M, et al. Eur J Surg Oncol. 2004 Jun;30(5):465-8. doi: 10.1016/j.ejso.2004.03.008. Eur J Surg Oncol. 2004. PMID: 15135470 Review. - [Regulation of hypoxia-inducible factor-1alpha expression].
Du KM, Chen GQ, Chen Z. Du KM, et al. Ai Zheng. 2004 Sep;23(9):1098-102. Ai Zheng. 2004. PMID: 15363211 Review. Chinese. - HIF at the crossroads between ischemia and carcinogenesis.
Paul SA, Simons JW, Mabjeesh NJ. Paul SA, et al. J Cell Physiol. 2004 Jul;200(1):20-30. doi: 10.1002/jcp.10479. J Cell Physiol. 2004. PMID: 15137054 Review.
Cited by
- Asparagine Hydroxylation is a Reversible Post-translational Modification.
Rodriguez J, Haydinger CD, Peet DJ, Nguyen LK, von Kriegsheim A. Rodriguez J, et al. Mol Cell Proteomics. 2020 Nov;19(11):1777-1789. doi: 10.1074/mcp.RA120.002189. Epub 2020 Aug 5. Mol Cell Proteomics. 2020. PMID: 32759169 Free PMC article. - Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma.
Zhao H, Wu Y, Chen Y, Liu H. Zhao H, et al. Int J Clin Oncol. 2015 Dec;20(6):1233-43. doi: 10.1007/s10147-015-0848-x. Epub 2015 Jun 16. Int J Clin Oncol. 2015. PMID: 26077139 - Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions.
Chen Z, Han F, Du Y, Shi H, Zhou W. Chen Z, et al. Signal Transduct Target Ther. 2023 Feb 17;8(1):70. doi: 10.1038/s41392-023-01332-8. Signal Transduct Target Ther. 2023. PMID: 36797231 Free PMC article. Review. - Effects of histone deacetylase inhibitors on HIF-1.
Liang D, Kong X, Sang N. Liang D, et al. Cell Cycle. 2006 Nov 1;5(21):2430-5. doi: 10.4161/cc.5.21.3409. Epub 2006 Sep 13. Cell Cycle. 2006. PMID: 17102633 Free PMC article. Review. - Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain.
Kaluz S, Kaluzová M, Stanbridge EJ. Kaluz S, et al. Mol Cell Biol. 2006 Aug;26(15):5895-907. doi: 10.1128/MCB.00552-06. Mol Cell Biol. 2006. PMID: 16847340 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources